

# Angelo Sala

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2055047/publications.pdf>

Version: 2024-02-01

120  
papers

4,537  
citations

81839

39  
h-index

110317

64  
g-index

127  
all docs

127  
docs citations

127  
times ranked

5083  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bioactive Compounds in Edible Oils and Their Role in Oxidative Stress and Inflammation. <i>Frontiers in Physiology</i> , 2021, 12, 659551.	1.3	37
2	Effects of Mediterranean Diet or Low-Fat Diet on Blood Fatty Acids in Patients with Coronary Heart Disease. A Randomized Intervention Study. <i>Nutrients</i> , 2021, 13, 2389.	1.7	5
3	Citrus flavonoids effects on human umbilical vein. <i>Journal of Functional Foods</i> , 2021, 86, 104731.	1.6	1
4	Blood Fatty Acids Profile in MIS-C Children. <i>Metabolites</i> , 2021, 11, 721.	1.3	5
5	The Atlas of Inflammation Resolution (AIR). <i>Molecular Aspects of Medicine</i> , 2020, 74, 100894.	2.7	110
6	Montelukast Use Decreases Cardiovascular Events in Asthmatics. <i>Frontiers in Pharmacology</i> , 2020, 11, 611561.	1.6	14
7	Rapid Metabolization of Protectin D1 by $\hat{1}^2$ -Oxidation of Its Polar Head Chain. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9961-9975.	2.9	18
8	CHF6001 Inhibits NF- $\hat{1}$ B Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice. <i>Frontiers in Pharmacology</i> , 2019, 10, 1337.	1.6	7
9	Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation. <i>Frontiers in Pharmacology</i> , 2019, 10, 938.	1.6	13
10	Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8443-8460.	2.9	19
11	Montelukast and cardiovascular events: Insights from observational retrospective study. , 2019, , .		0
12	Two-pronged approach to anti-inflammatory therapy through the modulation of the arachidonic acid cascade. <i>Biochemical Pharmacology</i> , 2018, 158, 161-173.	2.0	41
13	Increased dietary levels of $\hat{1}\pm$ -linoleic acid inhibit mammary tumor growth and metastasis. <i>European Journal of Nutrition</i> , 2017, 56, 509-519.	1.8	31
14	Proanthocyanidins from <i>Vitis vinifera</i> inhibit oxidative stress-induced vascular impairment in pulmonary arteries from diabetic rats. <i>Phytomedicine</i> , 2017, 25, 39-44.	2.3	18
15	The role of montelukast in cardiovascular events. <i>Atherosclerosis</i> , 2017, 263, e150.	0.4	1
16	Continuous wound infusion with chloroprocaine in a pig model of surgical lesion: drug absorption and effects on inflammatory response. <i>Journal of Pain Research</i> , 2017, Volume 10, 2515-2524.	0.8	7
17	Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk. <i>Current Medicinal Chemistry</i> , 2017, 24, 3218-3230.	1.2	6
18	Prostaglandin E2 possesses different potencies in inducing Vascular Endothelial Growth Factor and Interleukin-8 production in COPD human lung fibroblasts. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2016, 106, 11-18.	1.0	21

#	ARTICLE	IF	CITATIONS
19	In vitro pharmacological evaluation of multitarget thromboxane prostanoid receptor/COX-2 agents: A possible strategy to solve the cardiovascular issues of COXIBs. <i>Atherosclerosis</i> , 2016, 252, e59.	0.4	0
20	Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers. <i>Journal of Breath Research</i> , 2016, 10, 017102.	1.5	48
21	In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition. <i>Pharmacological Research</i> , 2016, 103, 132-143.	3.1	10
22	Monitoring inflammation and airway remodeling by fluorescence molecular tomography in a chronic asthma model. <i>Journal of Translational Medicine</i> , 2015, 13, 336.	1.8	23
23	CHF6001 I: A Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Topical Pulmonary Administration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 559-567.	1.3	67
24	CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration <sup>27</sup> In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 568-578.	1.3	40
25	IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases. <i>Immunobiology</i> , 2015, 220, 954-963.	0.8	81
26	Antiinflammatory and antioxidant effects of H <sub>2</sub> O <sub>2</sub> generated by natural sources in IL1 $\beta$ -treated human endothelial cells. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 121, 190-198.	1.0	10
27	Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: Signaling through the CysLT <sub>2</sub> receptor. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 115-125.	1.0	19
28	Beta2-adrenergic activity modulates vascular tone regulation in lecithin:cholesterol acyltransferase knockout mice. <i>Vascular Pharmacology</i> , 2015, 74, 114-121.	1.0	16
29	Transcellular biosynthesis of eicosanoid lipid mediators. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 377-382.	1.2	71
30	Azithromycin inhibits nuclear factor $\kappa$ B activation during lung inflammation: an in vivo imaging study. <i>Pharmacology Research and Perspectives</i> , 2014, 2, e00058.	1.1	40
31	Cyclooxygenase-1 and Prostacyclin Production by Endothelial Cells in the Presence of Mild Oxidative Stress. <i>PLoS ONE</i> , 2013, 8, e56683.	1.1	28
32	Microrna 143 $\beta$ 145 Deficiency Impairs Vascular Function. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 467-474.	1.0	29
33	Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists $\beta$ COX $\beta$ Inhibitors. <i>ChemMedChem</i> , 2012, 7, 1647-1660.	1.6	28
34	Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. <i>Pharmacological Research</i> , 2012, 66, 343-348.	3.1	27
35	The pulmonary pharmacology of [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide] (2NTX-99), an anti-atherotrombotic compound with therapeutic potential in pathological conditions that target lung vasculature. <i>Prostaglandins and Other Lipid Mediators</i> . 2012. 98. 116-121.	1.0	0
36	Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT <sub>2</sub> receptor. <i>FASEB Journal</i> , 2011, 25, 3519-3528.	0.2	27

#	ARTICLE	IF	CITATIONS
37	Biomarkers Of Inflammation And Oxidative Stress In Patients With COPD And Healthy Smokers. , 2010, , .		0
38	Estrogen Receptor- $\alpha$ as a Drug Target Candidate for Preventing Lung Inflammation. <i>Endocrinology</i> , 2010, 151, 174-184.	1.4	61
39	Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2010, 298, L261-L269.	1.3	79
40	Transcellular biosynthesis of eicosanoids. <i>Pharmacological Reports</i> , 2010, 62, 503-510.	1.5	97
41	Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk. <i>Trends in Pharmacological Sciences</i> , 2010, 31, 102-107.	4.0	40
42	Estrogen Receptor- $\alpha$ as a Drug Target Candidate for Preventing Lung Inflammation. <i>Endocrine Reviews</i> , 2009, 30, 930-930.	8.9	0
43	Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8296-8301.	3.3	78
44	Critical role of COX-1 in prostacyclin production by human endothelial cells under modification of hydroperoxide tone. <i>FASEB Journal</i> , 2009, 23, 605-612.	0.2	26
45	Cysteinyl Leukotriene-1 Receptor Activation in a Human Bronchial Epithelial Cell Line Leads to Signal Transducer and Activator of Transcription 1-Mediated Eosinophil Adhesion. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 325, 1024-1030.	1.3	28
46	Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends. <i>Medicinal Research Reviews</i> , 2007, 27, 469-527.	5.0	150
47	A new class of nitric oxide-releasing derivatives of cetirizine; pharmacological profile in vascular and airway smooth muscle preparations. <i>British Journal of Pharmacology</i> , 2007, 151, 35-44.	2.7	13
48	Antagonism of thromboxane receptors by diclofenac and lumiracoxib. <i>British Journal of Pharmacology</i> , 2007, 152, 1185-1195.	2.7	29
49	Pharmacological modulation of the leukotriene pathway in allergic airway disease. <i>Drug Discovery Today</i> , 2007, 12, 404-412.	3.2	76
50	From Field to Health: A Simple Way To Increase the Nutraceutical Content of Grape As Shown by NO-Dependent Vascular Relaxation. <i>Journal of Agricultural and Food Chemistry</i> , 2006, 54, 5344-5349.	2.4	37
51	Isoprostanes and Oxidative Stress in Off-Pump and On-Pump Coronary Bypass Surgery. <i>Annals of Thoracic Surgery</i> , 2006, 81, 562-567.	0.7	58
52	eNOS, COX-2, and prostacyclin production are impaired in endothelial cells from diabetics. <i>Biochemical and Biophysical Research Communications</i> , 2006, 339, 188-190.	1.0	33
53	Pharmacological Characterization of ZNTX-99 [4-Methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a Potential Antiatherothrombotic Agent with Antithromboxane and Nitric Oxide Donor Activity in Platelet and Vascular Preparations. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 830-837.	1.3	9
54	Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 1361-1369.	2.7	133

#	ARTICLE	IF	CITATIONS
55	Reduced in vivo oxidative stress following 5-methyltetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. <i>British Journal of Haematology</i> , 2005, 131, 100-108.	1.2	17
56	Lipid Peroxidation and 5-Lipoxygenase Activity in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 838-843.	2.5	55
57	Cysteinyl leukotriene receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl leukotrienes. <i>FASEB Journal</i> , 2004, 18, 842-844.	0.2	66
58	Role of sodium in intracellular calcium elevation and leukotriene B <sub>4</sub> formation by receptor-mediated activation of human neutrophils. <i>Biochemical Pharmacology</i> , 2004, 67, 385-393.	2.0	2
59	Activation of the orphan nuclear receptor ROR $\alpha$ counteracts the proliferative effect of fatty acids on prostate cancer cells: Crucial role of 5-lipoxygenase. <i>International Journal of Cancer</i> , 2004, 112, 87-93.	2.3	45
60	Increased prostaglandin E <sub>2</sub> concentrations and cyclooxygenase-2 expression in asthmatic subjects with sputum eosinophilia. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 709-716.	1.5	107
61	IL-4-Induced Lipid Mediators Class Switching in Human Normal Mononuclear Phagocytes. <i>Advances in Experimental Medicine and Biology</i> , 2003, 525, 15-18.	0.8	0
62	Leukotriene B <sub>4</sub> Production in Human Mononuclear Phagocytes Is Modulated by Interleukin-4-Induced 15-Lipoxygenase. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 868-875.	1.3	29
63	$\beta$ 2-Integrin-Dependent Neutrophil Adhesion Induced by Minimally Modified Low-Density Lipoproteins Is Mainly Mediated by F <sub>2</sub> -Isoprostanes. <i>Circulation</i> , 2002, 106, 2434-2441.	1.6	22
64	Neutrophils, Endothelial Cells, and Cysteinyl Leukotrienes: A New Approach to Neutrophil-Dependent Inflammation?. <i>Biochemical and Biophysical Research Communications</i> , 2001, 283, 1003-1006.	1.0	58
65	The Cyclooxygenase-2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat. <i>Neuroscience Letters</i> , 2001, 303, 91-94.	1.0	69
66	The Potential Role of Tocopherol in Asthma and Allergies. <i>BioDrugs</i> , 2001, 15, 81-86.	2.2	17
67	Estrogen Prevents the Lipopolysaccharide-Induced Inflammatory Response in Microglia. <i>Journal of Neuroscience</i> , 2001, 21, 1809-1818.	1.7	415
68	Leukotrienes as targets in cardiovascular disease. <i>Clinical and Experimental Allergy Reviews</i> , 2001, 1, 313-316.	0.3	0
69	Synthesis of 19-[(2-azido-5-iodo)-benzoyloxy]-LTA <sub>4</sub> and enzymatic conversion to the LTC <sub>4</sub> analogue. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 665-668.	1.0	2
70	Tramadol anti-inflammatory activity is not related to a direct inhibitory action on prostaglandin endoperoxide synthases. <i>European Journal of Pain</i> , 2000, 4, 413-415.	1.4	31
71	15(S)-HETE modulates LTB <sub>4</sub> production and neutrophil chemotaxis in chronic bronchitis. <i>American Journal of Physiology - Cell Physiology</i> , 2000, 279, C1249-C1258.	2.1	66
72	Olive Phenol Hydroxytyrosol Prevents Passive Smoking-Induced Oxidative Stress. <i>Circulation</i> , 2000, 102, 2169-2171.	1.6	168

#	ARTICLE	IF	CITATIONS
73	Leukotrienes in Cardiovascular Diseases. American Journal of Respiratory and Critical Care Medicine, 2000, 161, S112-S116.	2.5	49
74	Effect of Endogenous and Exogenous Prostaglandin E2 on Interleukin-1 $\beta$ -Induced Cyclooxygenase-2 Expression in Human Airway Smooth-Muscle Cells. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 2272-2277.	2.5	47
75	Monoclonal Anti-CD18 Antibody Prevents Transcellular Biosynthesis of Cysteinyl Leukotrienes In Vitro and In Vivo and Protects Against Leukotriene-Dependent Increase in Coronary Vascular Resistance and Myocardial Stiffness. Circulation, 2000, 101, 1436-1440.	1.6	30
76	Olive Oils Rich in Natural Catecholic Phenols Decrease Isoprostane Excretion in Humans. Biochemical and Biophysical Research Communications, 2000, 278, 797-799.	1.0	152
77	15-Lipoxygenase expression and 15(S)-hydroxyeicosatetraenoic acid release and reincorporation in induced sputum of asthmatic subjects. Journal of Allergy and Clinical Immunology, 2000, 105, 711-716.	1.5	48
78	Interleukin-4 Enhances 15-Lipoxygenase Activity and Incorporation of 15(S)-HETE into Cellular Phospholipids in Cultured Pulmonary Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 1999, 20, 61-68.	1.4	40
79	Differential Metabolism of Exogenous and Endogenous Arachidonic Acid in Human Neutrophils. Journal of Biological Chemistry, 1999, 274, 28264-28269.	1.6	49
80	Cyclooxygenase-2-dependent generation of 8-epiprostaglandin F <sub>2</sub> $\alpha$ by lipopolysaccharide-activated J774 macrophages. Inflammation Research, 1999, 48, 503-508.	1.6	18
81	IL-4 and IgE $\alpha$ anti-IgE modulation of 15(S)-hydroxyeicosatetraenoic acid release by mononuclear phagocytes. Journal of Allergy and Clinical Immunology, 1999, 103, 159-164.	1.5	6
82	Transcellular biosynthesis of leukotrienes: A unique mode of cell communication. , 1999, , 113-124.		1
83	Therapeutic intervention with LT synthase inhibitors and receptor antagonists in cardiovascular inflammation events. Drug News and Perspectives, 1999, 12, 91.	1.9	0
84	Inhibition of prostanoid synthesis protects against neuronal damage induced by focal ischemia in rat brain. Neuroscience Letters, 1998, 257, 123-126.	1.0	30
85	Neutrophil-Endothelial Cells Cooperation in the Handling of Leukotrienes: Role in Coronary Inflammation. Medical Science Symposia Series, 1998, , 239-245.	0.0	0
86	Cyclooxygenase-2 and synthesis of PGE2 in human bronchial smooth-muscle cells.. American Journal of Respiratory and Critical Care Medicine, 1997, 155, 864-868.	2.5	47
87	14,15-Dehydroleukotriene A4: a specific substrate for leukotriene C4 synthase. Biochemical Journal, 1997, 328, 225-229.	1.7	8
88	Pharmacological modulation of human platelet leukotriene C4-synthase. Biochemical Pharmacology, 1997, 53, 905-908.	2.0	10
89	Comparative analysis of isolated human bronchi contraction and biosynthesis of cysteinyl leukotrienes using a direct 5-lipoxygenase inhibitor. Biochemical Pharmacology, 1997, 54, 437-442.	2.0	7
90	INHIBITION OF LEUKOCYTE LEUKOTRIENE B4 PRODUCTION BY AN OLIVE OIL-DERIVED PHENOL IDENTIFIED BY MASS-SPECTROMETRY. Thrombosis Research, 1997, 87, 315-322.	0.8	58

#	ARTICLE	IF	CITATIONS
91	Nitric oxide modulation of transcellular biosynthesis of cys-leukotrienes in rabbit leukocyte-perfused heart. <i>British Journal of Pharmacology</i> , 1997, 120, 1128-1134.	2.7	16
92	Synthesis and biological evaluation of 14,15-dehydro-LTA4 analog. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1997, 7, 105-108.	1.0	7
93	Transcellular Synthesis of CYS-LT: From Isolated Cells to Complex Organ System. <i>Advances in Experimental Medicine and Biology</i> , 1997, 433, 95-98.	0.8	3
94	Nasal neutrophilia and release of myeloperoxidase induced by nasal challenge with platelet activating factor: Different degrees of responsiveness in atopic and nonatopic subjects*. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 947-954.	1.5	11
95	Leukotriene A4, and not leukotriene B4, is the main 5-lipoxygenase metabolite released by bovine leukocytes. <i>FEBS Letters</i> , 1996, 388, 94-98.	1.3	19
96	Consequences Of Transcellular Biosynthesis Of Leukotriene C4 On Organ Function. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1996, 26, 28-36.	0.5	3
97	Release of Leukotriene A4 Leukotriene B4 from Human Polymorphonuclear Leukocytes. <i>Journal of Biological Chemistry</i> , 1996, 271, 17944-17948.	1.6	89
98	Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996, 153, 572-575.	2.5	252
99	Vasoconstriction to Polymorphonuclear Leukocytes in the Isolated, Perfused Rabbit Heart: Inhibition by Prostacyclin Mimetics. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 27, 680-685.	0.8	19
100	Polymorphonuclear-Endothelial Cell Interactions and the Control of Coronary Vasculature. , 1996, , 89-97.		0
101	Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1994, 150, 287-287.	2.5	0
102	Effects of loratadine on cytosolic Ca <sup>2+</sup> levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. <i>European Journal of Pharmacology</i> , 1994, 266, 219-227.	2.7	35
103	Effects of nedocromil sodium on bronchospasm and HS-NCA release induced by allergen inhalation in asthmatic patients. <i>Clinical and Experimental Allergy</i> , 1994, 24, 281-287.	1.4	3
104	An improved assay for urinary LTE4. <i>Prostaglandins</i> , 1994, 47, 281-292.	1.2	12
105	Transcellular metabolism of leukotrienes and regulation of cardiac function. <i>Pharmacological Research</i> , 1994, 30, 353.	3.1	0
106	Formation of sulphidopeptide leukotrienes by cell-cell interaction causes coronary vasoconstriction in isolated, cell-perfused heart of rabbit. <i>British Journal of Pharmacology</i> , 1993, 110, 1206-1212.	2.7	56
107	Synthesis of leukotrienes and its pharmacological control in the rabbit heart. <i>Pharmacological Research</i> , 1992, 25, 103-104.	3.1	0
108	Actual Role of Prostaglandins in Inflammation. <i>Drug Investigation</i> , 1991, 3, 4-9.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Direct airway injury results in elevated levels of sulfidopeptide leukotrienes, detectable in airway secretions. Prostaglandins, 1991, 42, 1-7.	1.2	17
110	Appearance of Urinary Metabolites of LTE <sub>4</sub> in Human Subjects. Annals of the New York Academy of Sciences, 1991, 629, 105-111.	1.8	7
111	Negative ion tandem mass spectrometry of leukotriene E <sub>4</sub> , and LTE <sub>4</sub> , metabolites: Identification of LTE <sub>4</sub> , in human urine. Journal of the American Society for Mass Spectrometry, 1991, 2, 314-321.	1.2	18
112	[11] Quantitation of sulfidopeptide leukotrienes in biological fluids by gas chromatography-mass spectrometry. Methods in Enzymology, 1990, 187, 90-98.	0.4	12
113	Sulfidopeptide leukotriene and acute respiratory distress syndrome. Pharmacological Research, 1990, 22, 443.	3.1	0
114	Mediator release after endobronchial antigen challenge in patients with respiratory allergy. Journal of Allergy and Clinical Immunology, 1990, 85, 906-913.	1.5	73
115	Prostaglandins and gastric mucosal protection by esaprazole in rats. European Journal of Pharmacology, 1990, 187, 19-25.	1.7	1
116	Evidence of PAF-acether Metabolic Pathway Activation in Antigen Challenge of Upper Respiratory Airways. The American Review of Respiratory Disease, 1989, 140, 142-147.	2.9	56
117	Inhibition by lipoxigenase products of TXA <sub>2</sub> -like responses of platelets and vascular smooth muscle. Biochemical Pharmacology, 1988, 37, 1275-1280.	2.0	62
118	Behavior and Clinical Relevance of Histamine and Leukotrienes C <sub>4</sub> and B <sub>4</sub> in Grass Pollen-Induced Rhinitis. The American Review of Respiratory Disease, 1987, 136, 357-362.	2.9	120
119	PGD <sub>2</sub> induces pulmonary hyperresponsiveness to acetylcholine in vivo in the guinea-pig. Autonomic and Autacoid Pharmacology, 1987, 7, 281-285.	0.7	6
120	Perspectives of Analytical Methods for Eicosanoids. , 0, , 95-102.		0